Literature DB >> 22494291

Serum fibroblast growth factor 21 is associated with renal function and chronic kidney disease in community-dwelling adults.

Candace Crasto, Richard D Semba, Kai Sun, Luigi Ferrucci.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22494291      PMCID： PMC3325515          DOI： 10.1111/j.1532-5415.2011.03879.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN： 0002-8614            Impact factor:   5.562


× No keyword cloud information.
  8 in total

1.  Plasma FGF21 displays a circadian rhythm during a 72-h fast in healthy female volunteers.

Authors:  Birgitte Andersen; Henning Beck-Nielsen; Kurt Højlund
Journal:  Clin Endocrinol (Oxf)       Date:  2011-10       Impact factor: 3.478

2.  Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway.

Authors:  Mary D L Chau; Jiaping Gao; Qing Yang; Zhidan Wu; Jesper Gromada
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

3.  Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity.

Authors:  Fredirick L Mashili; Reginald L Austin; Atul S Deshmukh; Tomas Fritz; Kenneth Caidahl; Katrin Bergdahl; Juleen R Zierath; Alexander V Chibalin; David E Moller; Alexei Kharitonenkov; Anna Krook
Journal:  Diabetes Metab Res Rev       Date:  2011-03       Impact factor: 4.876

4.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

5.  Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans.

Authors:  Xinmei Zhang; Dennis C Y Yeung; Michal Karpisek; David Stejskal; Zhi-Guang Zhou; Feng Liu; Rachel L C Wong; Wing-Sun Chow; Annette W K Tso; Karen S L Lam; Aimin Xu
Journal:  Diabetes       Date:  2008-02-05       Impact factor: 9.461

6.  Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile.

Authors:  Zhuofeng Lin; Zhen Wu; Xiaojing Yin; Yanlong Liu; Xinxin Yan; Shaoqiang Lin; Jian Xiao; Xiaojie Wang; Wenke Feng; Xiaokun Li
Journal:  PLoS One       Date:  2010-12-29       Impact factor: 3.240

7.  High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects.

Authors:  Cheng Chen; Bernard M Y Cheung; Annette W K Tso; Yudong Wang; Lawrence S C Law; Kwok Leung Ong; Nelson M S Wat; Aimin Xu; Karen S L Lam
Journal:  Diabetes Care       Date:  2011-07-12       Impact factor: 19.112

8.  Serum levels of the adipokine FGF21 depend on renal function.

Authors:  Sebastian Stein; Anette Bachmann; Ulrike Lössner; Jürgen Kratzsch; Matthias Blüher; Michael Stumvoll; Mathias Fasshauer
Journal:  Diabetes Care       Date:  2008-10-07       Impact factor: 17.152
  8 in total
  18 in total

Review 1.  Fibroblast growth factor 21 in chronic kidney disease.

Authors:  Paulo Giovanni de Albuquerque Suassuna; Rogério Baumgratz de Paula; Hélady Sanders-Pinheiro; Orson W Moe; Ming-Chang Hu
Journal:  J Nephrol       Date:  2018-11-14       Impact factor: 3.902

Review 2.  Immunologic and endocrine functions of adipose tissue: implications for kidney disease.

Authors:  Qingzhang Zhu; Philipp E Scherer
Journal:  Nat Rev Nephrol       Date:  2017-12-04       Impact factor: 28.314

Review 3.  Cardiac actions of fibroblast growth factor 23.

Authors:  Christian Faul
Journal:  Bone       Date:  2016-10-07       Impact factor: 4.398

4.  Possible role of fibroblast growth factor 21 on atherosclerosis via amelioration of endoplasmic reticulum stress-mediated apoptosis in apoE(-/-) mice.

Authors:  Xi Wu; Yong-Fen Qi; Jin-Rui Chang; Wei-Wei Lu; Jin-Sheng Zhang; Shao-Ping Wang; Shu-Juan Cheng; Ming Zhang; Qian Fan; Yuan Lv; Hui Zhu; Man-Kun Xin; Yun Lv; Jing-Hua Liu
Journal:  Heart Vessels       Date:  2014-08-05       Impact factor: 2.037

5.  Circulating levels of fibroblast growth factor 21 in early-stage diabetic kidney disease.

Authors:  A Esteghamati; A Khandan; A Momeni; A Behdadnia; A Ghajar; M S Nikdad; S Noshad; M Nakhjavani; M Afarideh
Journal:  Ir J Med Sci       Date:  2017-02-08       Impact factor: 1.568

6.  Fibroblast Growth Factor 21 (FGF-21) in Peritoneal Dialysis Patients: Natural History and Metabolic Implications.

Authors:  Elena González; Juan J Díez; M Auxiliadora Bajo; Gloria del Peso; Cristina Grande; Olaia Rodríguez; Mariana Díaz-Almirón; Pedro Iglesias; Rafael Selgas
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

7.  Fibroblast growth factor 21 (FGF21) in children and adolescents with chronic kidney disease.

Authors:  Z Gamrot; P Adamczyk; E Świętochowska; D Roszkowska-Bjanid; J Gamrot; M Szczepańska
Journal:  Physiol Res       Date:  2020-05-29       Impact factor: 1.881

8.  FGF21 prevents low-protein diet-induced renal inflammation in aged mice.

Authors:  Han Fang; Sujoy Ghosh; Landon C Sims; Kirsten P Stone; Cristal M Hill; Denisha Spires; Daria V Ilatovskaya; Christopher D Morrison; Thomas W Gettys; Krisztian Stadler
Journal:  Am J Physiol Renal Physiol       Date:  2021-06-21

9.  Attenuation of hyperlipidemia- and diabetes-induced early-stage apoptosis and late-stage renal dysfunction via administration of fibroblast growth factor-21 is associated with suppression of renal inflammation.

Authors:  Chi Zhang; Minglong Shao; Hong Yang; Liangmiao Chen; Lechu Yu; Weitao Cong; Haishan Tian; Fangfang Zhang; Peng Cheng; Litai Jin; Yi Tan; Xiaokun Li; Lu Cai; Xuemian Lu
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

Review 10.  Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis.

Authors:  Giovanni Musso; Roberto Gambino; James H Tabibian; Mattias Ekstedt; Stergios Kechagias; Masahide Hamaguchi; Rolf Hultcrantz; Hannes Hagström; Seung Kew Yoon; Phunchai Charatcharoenwitthaya; Jacob George; Francisco Barrera; Svanhildur Hafliðadóttir; Einar Stefan Björnsson; Matthew J Armstrong; Laurence J Hopkins; Xin Gao; Sven Francque; An Verrijken; Yusuf Yilmaz; Keith D Lindor; Michael Charlton; Robin Haring; Markus M Lerch; Rainer Rettig; Henry Völzke; Seungho Ryu; Guolin Li; Linda L Wong; Mariana Machado; Helena Cortez-Pinto; Kohichiroh Yasui; Maurizio Cassader
Journal:  PLoS Med       Date:  2014-07-22       Impact factor: 11.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.